[1]祁媛媛,闫春晓,金翠华,等.多次玻璃体内注射抗VEGF药物对眼底血管性疾病患者角膜组织形态的影响[J].眼科新进展,2024,44(3):230-234.[doi:10.13389/j.cnki.rao.2024.0045]
　QI Yuanyuan,YAN Chunxiao,JIN Cuihua,et al.Effects of repeated intravitreal injections of anti-vascular endothelial growth factor drugs on corneal morphology in patients with fundus vascular diseases[J].Recent Advances in Ophthalmology,2024,44(3):230-234.[doi:10.13389/j.cnki.rao.2024.0045]
点击复制

多次玻璃体内注射抗VEGF药物对眼底血管性疾病患者角膜组织形态的影响/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
44卷
期数:
2024年3期
页码:
230-234
栏目:
应用研究
出版日期:
2024-03-05

文章信息/Info

Title:
Effects of repeated intravitreal injections of anti-vascular endothelial growth factor drugs on corneal morphology in patients with fundus vascular diseases
作者:
祁媛媛; 闫春晓; 金翠华; 袁琳慧; 李胜; 张立军
116044　辽宁省大连市，大连医科大学（祁媛媛，闫春晓，袁琳慧，张立军）;116033　辽宁省大连市，大连医科大学附属大连市第三人民医院眼科 辽宁省角膜与眼表疾病重点实验室（祁媛媛，闫春晓，金翠华，袁琳慧,李胜,张立军）
Author(s):
QI Yuanyuan1; 2; YAN Chunxiao1; 2; JIN Cuihua2; YUAN Linhui1; 2; LI Sheng2; ZHANG Lijun1; 2
1.Dalian Medical University,Dalian 116044,Liaoning Province,China
2.Key Laboratory of Corneal and Ocular Surface Diseases Research of Liaoning Province & Department of Ophthalmology,the Third People’s Hospital Affiliated to Dalian Medical University,Dalian 116033,Liaoning Province,China
关键词:
抗血管内皮生长因子; 内皮细胞密度; 角膜神经; 阿柏西普; 雷珠单抗
Keywords:
anti-vascular endothelial growth factor;  endothelial cell density;  corneal nerve;  aflibercept;  ranibizumab
分类号:
R772.2
DOI:
10.13389/j.cnki.rao.2024.0045
文献标志码:
A
摘要:
目的　探讨多次玻璃体内注射雷珠单抗和阿柏西普对湿性老年性黄斑变性(nAMD)、糖尿病黄斑水肿（DME）、视网膜静脉阻塞(RVO)患者角膜组织形态的影响。
方法　前瞻性临床研究。选取2021年6月至2022年6月在我院眼内科注射中心治疗的患者共64例（64眼）作为研究对象；其中nAMD患者19例，DME 患者20例，RVO患者25例。阿柏西普（40 g·L-1）治疗29例，雷珠单抗（10 g·L-1）治疗35例。所有入组病例均选取单眼注射，采取3+PRN的随访治疗方法。使用共聚焦显微镜行角膜神经检查，使用角膜内皮显微镜进行角膜厚度及角膜内皮细胞检查。比较nAMD、DME、RVO患者多次玻璃体内注射抗VEGF药物后角膜厚度、内皮细胞密度、变异系数、平均面积、六角形细胞比例、神经纤维长度、神经纤维密度,比较每次注射不同药物后1个月与基线时上述指标变化。
结果　术前，DME组患者内皮细胞密度低于nAMD组和RVO组，DME组患者内皮细胞平均面积高于nAMD组和RVO组，差异均有统计学意义（均为P<0.05），三种不同疾病患者其余指标差异均无统计学意义（均为P>0.05）。注射抗VEGF药物3次后，DME组患者内皮细胞密度低于nAMD组和RVO组，内皮细胞平均面积高于nAMD组和RVO组，差异均有统计学意义（均为P<0.05）；DME组患者神经纤维长度短于nAMD组和RVO组，差异均有统计学意义（均为P<0.05）。自从第2次注射阿柏西普后，nAMD组患者内皮细胞密度均较术前减少，差异均有统计学意义（均为P<0.05）；每次注射后六角形细胞比例均较术前减少，差异均有统计学意义（均为P<0.05）；其余指标注射后与术前相比，差异均无统计学意义（均为P>0.05）。自从第2次注射雷珠单抗后，RVO组患者内皮细胞密度均较术前减少，差异均有统计学意义（均为P<0.05）。
结论　多次玻璃体内注射抗VEGF药物会一定程度降低角膜内皮六角形细胞比例及内皮细胞密度，注射药物后DME组的神经纤维长度显著低于nAMD组和RVO组。
Abstract:
Objective　To observe the effects of repeated intravitreal injections of ranibizumab and aflibercept on corneal morphology of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) or retinal vein obstruction (RVO).
Methods　In this prospective study, 64 patients (64 eyes) who underwent therapy in the injection center of the Ophthalmology Department of our hospital from June 2021 to June 2022 were enrolled, including 19 nAMD patients, 20 DME patients and 25 RVO patients. Among these patients, 29 were treated with aflibercept (40 g·L-1) and 35 were treated with ranibizumab (10 g·L-1). Monocular injections were adopted for all patients, and 3+pro re nata (PRN) therapy was used. Confocal microscope was used for corneal nerve examination, and corneal endothelial microscope was used to measure corneal thickness (CT) and corneal endothelial cells. The CT, corneal endothelial cell density (ECD), coefficient of variation (CV), average cell size (ACS), proportion of hexagonal cells (Hex %), corneal nerve fiber length (CNFL), corneal nerve fiber density (CNFD) of patients with nAMD, DME and RVO after repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs were compared, and those parameters at 1 month after injection of different anti-VEGF drugs were compared with the baseline.
Results　Before injection, ECD in the DME group was lower than that in the nAMD and RVO groups, and the ACS in the DME group was higher than that in the nAMD and RVO groups (all P<0.05). There was no significant difference in the other indexes among the three groups (all P>0.05). After 3 injections of anti-VEGF drugs, the ECD in the DME group was lower than that in the nAMD and RVO groups, the ACS in the DME group was higher than that in the nAMD and RVO groups, and the CNFL in the DME group was lower than that in the nAMD and RVO groups (all P<0.05). The ECD decreased compared with that before injection from the 2nd injection of aflibercept in the nAMD group (all P<0.05). Hex % decreased significantly after each injection compared with the baseline (all P<0.05). Other indexes have no significant differences from the baseline (all P>0.05). In the RVO group, ECD decreased from the 2nd ranibizumab injection compared with the baseline (all P<0.05).
Conclusion　Repeated intravitreal injections of anti-VEGF drugs can reduce the Hex % and ECD to a certain extent. After injections, CNFL in the DME group is significantly lower than that in the nAMD and RVO groups.

参考文献/References:

［1］　RICCI F,BANDELLO F,NAVARRA P,STAURENGHI G,STUMPP M,ZARBIN M.Neovascular age-related macular degeneration:therapeutic management and new-upcoming approaches［J］.Int J Mol Sci,2020,21(21):8242.
［2］　AMOAKU W M,GHANCHI F,BAILEY C,BANERJEE S,BANERJEE S,DOWNEY L,et al.Diabetic retinopathy and diabetic macular oedema pathways and management:UK Consensus Working Group［J］.Eye,2020,34(Suppl 1):1-51.
［3］　SCHMIDT-ERFURTH U,GARCIA-ARUMI J,GERENDAS B S,MIDENA E,SIVAPRASAD S,TADAYONI R,et al.Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA)［J］.Ophthalmologica,2019,242(3):123-162.
［4］　CABRAL T,LIMA L H,POLIDO J,DUONG J,OKUDA ,OSHIMA A,et al.Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration［J］.Int J Retina Vitreous,2017,3:6.
［5］　PHILIPP W,SPEICHER L,HUMPEL C.Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas［J］.Invest Ophthalmol Vis Sci,2000,41(9):2514-2522.
［6］　DRATVIMAN-STOROBINSKY O,AVRAHAM-LUBIN B C R,HASANREISOGLU M,GOLDENBERG-COHEN N.Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization［J］.Mol Vis,2009,15:2326-2338.
［7］　MERZ P R,R?CKEL N,BALLIKAYA S,AUFFARTH G U,SCHMACK I.Effects of ranibizumab (Lucentis?) and bevacizumab (Avastin?) on human corneal endothelial cells［J］.BMC Ophthalmol,2018,18(1):316.
［8］　URBAN B,SZWABOWICZ M,BAKUNOWICZ-AZARCZYK A.Effect of repeated intravitreal ranibizumab and aflibercept injections on the Cornea in patients with age-related macular degeneration［J］.J Ophthalmol,2020,2020:4928905.
［9］　POLAT O A,?ENER H,ERKILIC K.Corneal nerve fiber and sensitivity loss after repeated intravitreal anti-VEGF injections:an in vivo confocal microscopy study［J］.Cornea,2021,41(3):317-321.
［10］　BOCK F,ONDERKA J,RUMMELT C,DIETRICH T,BACHMANN B,KRUSE F E,et al.Safety profile of topical VEGF neutralization at the cornea［J］.Invest Ophthalmol Vis Sci,2009,50(5):2095-2102.
［11］　FLAXEL C J,ADELMAN R A,BAILEY S T,FAWZI A,LIM J I,VEMULAKONDA G A,et al.Age-related macular degeneration preferred practice pattern?［J］.Ophthalmology,2020,127(1):P1-P65.
［12］　KITCHENS J W,DO D V,BOYER D S,THOMPSON D,GIBSON A,SAROJ N,et al.Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials［J］.Ophthalmology,2016,123(7):1511-1520.
［13］　MALONEY M H,PAYNE S R,HERRIN J,SANGARALINGHAM L R,SHAH N D,BARKMEIER A J.Risk of systemic adverse events after intravitreal bevacizumab,ranibizumab,and aflibercept in routine clinical practice［J］.Ophthalmology,2021,128(3):417-424.
［14］　GHARBIYA M,BRUSCOLINI A,SACCHETTI M,ROSSO P,CARITO V,SEGATTO M,et al.In vivo antivascular endothelial growth factor treatment induces corneal endothelium apoptosis in rabbits through changes in p75NTR-proNGF pathway［J］.J Cell Physiol,2018,233(11):8874-8883.
［15］　林杜生,周昭涛,黄晓琼,肖亮伊,张少斌.反复玻璃体内注射阿柏西普对黄斑水肿患者角膜的影响［J］.眼科新进展,2021,41(4):368-370,375.
LIN D S,ZHOU Z T,HUANG X Q,XIAO L Y,ZHANG S B.Effect of repeated intravitreal aflibercept injections on the cornea in patients with macular edema［J］.Rec Adv Ophthalmol,2021,41(4):368-370,375.
［16］　ARSLAN G D,GUVEN D,ALKAN A A,KACAR H,DEMIR M.Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea,anterior chamber,and intraocular pressure［J］.Cutan Ocul Toxicol,2019,38(4):344-348.
［17］　GUZEL H,BAKBAK B,KOYLU M T,GONUL S,OZTURK B,GEDIK S.The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema［J］.Cutan Ocul Toxicol,2017,36(1):5-8.
［18］　STORR-PAULSEN A,SINGH A,JEPPESEN H,NORREGAARD J C,THULESEN J.Corneal endothelial morphology and central thickness in patients with type II diabetes mellitus［J］.Acta Ophthalmol,2014,92(2):158-160.
［19］　STEWART M W,ROSENFELD P J.Predicted biological activity of intravitreal VEGF Trap［J］.Br J Ophthalmol,2008,92(5):667-668.
［20］　HE J,BAZAN H E.Neuroanatomy and neurochemistry of mouse cornea［J］.Invest Ophthalmol Vis Sci,2016,57(2):664-674.
［21］　MARFURT C F,COX J,DEEK S,DVORSCAK L.Anatomy of the human corneal innervation［J］.Exp Eye Res,2010,90(4):478-492.
［22］　DONG M,DI G,ZHANG X,ZHOU Q,SHI W.Subconjunctival bevacizumab injection impairs corneal innervations and epithelial wound healing in mice［J］.Invest Ophthalmol Vis Sci,2017,58(3):1469.
［23］　NICOLA P,KATIE E,RUSSELL ANTHONY W,PERKINS BRUCE A,MALIK RAYAZ A,NATHAN E.Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes［J］.Diabetes Care,2015,38(4):671-675.
［24］　SRINIVASAN S,DEHGHANI C,PRITCHARD N,EDWARDS K,RUSSELL A W,MALIK R A,et al.Ophthalmic and clinical factors that predict four-year development and worsening of diabetic retinopathy in type 1 diabetes［J］.J Diabetes Complications,2018,32(1):67-74.

相似文献/References:

[1]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[2]刘李平 宋徽 肖云 曹小鹏 白润 陈珍.玻璃体注射雷珠单抗治疗缺血型视网膜中央静脉阻塞的临床观察[J].眼科新进展,2013,33(11):000.
[3]刘晶晶,刘子扬,彭清.渗出型年龄相关性黄斑变性的抗血管内皮生长因子治疗进展[J].眼科新进展,2015,35(1):084.[doi:10.13389/j.cnki.rao.2015.0024]
　LIU Jing-Jing,LIU Zi-Yang,PENG Qing.Recent advances in anti-vascular endothelial growth factor for exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(3):084.[doi:10.13389/j.cnki.rao.2015.0024]
[4]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
　XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(3):1093.[doi:10.13389/j.cnki.rao.2016.0292]
[5]李松峰,邓光达,刘敬花,等.视网膜下液引流联合玻璃体内注射抗血管内皮生长因子药物治疗重度渗出性视网膜脱离Coats病的临床疗效[J].眼科新进展,2017,37(6):569.[doi:10.13389/j.cnki.rao.2017.0144]
　LI Song-Feng,DENG Guang-Da,LIU Jing-Hua,et al.Subretinal fluid drainage combined with intravitreal injection of anti-vascular endothelial growth factor in treatment of severe exudative retinal detachment Coats disease[J].Recent Advances in Ophthalmology,2017,37(3):569.[doi:10.13389/j.cnki.rao.2017.0144]
[6]吕亚男,宫媛媛.抗血管内皮生长因子（VEGF）治疗与视网膜下纤维化研究进展[J].眼科新进展,2017,37(6):583.[doi:10.13389/j.cnki.rao.2017.0148]
　LV Ya-Nan,GONG Yuan-Yuan.Anti-VEGF therapy and subretinal fibrosis[J].Recent Advances in Ophthalmology,2017,37(3):583.[doi:10.13389/j.cnki.rao.2017.0148]
[7]许晓璇,胡裕翔,程艺,等.早产儿视网膜病变抗血管内皮生长因子药物治疗新进展[J].眼科新进展,2018,38(9):883.[doi:10.13389/j.cnki.rao.2018.0209]
　XU Xiao-Xuan,HU Yu-Xiang,CHENG Yi,et al.New advances in anti-vascular endothelial growth factor drug therapy for retinopathy of prematurity[J].Recent Advances in Ophthalmology,2018,38(3):883.[doi:10.13389/j.cnki.rao.2018.0209]
[8]朱婷婷,王权,姜彩辉.糖尿病黄斑水肿治疗新进展[J].眼科新进展,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]
　ZHU Ting-Ting,WANG Quan,JIANG Cai-Hui.Recent research advances in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]
[9]宋晶,熊杰.康柏西普玻璃体内注射治疗特发性脉络膜新生血管[J].眼科新进展,2020,40(2):169.[doi:10.13389/j.cnki.rao.2020.0040]
　SONG Jing,XIONG Jie.Intravitreal injection of Conbercept in treatment of patients with idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(3):169.[doi:10.13389/j.cnki.rao.2020.0040]
[10]罗曼,陈晓隆.新生血管性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物治疗进展[J].眼科新进展,2020,40(6):582.[doi:10.13389/j.cnki.rao.2020.0134]
　LUO Man,CHEN Xiaolong.Progress in treatment of neovascular age-related macular degeneration with intravitreal injection of anti-VEGF drugs[J].Recent Advances in Ophthalmology,2020,40(3):582.[doi:10.13389/j.cnki.rao.2020.0134]

更新日期/Last Update: 2024-03-05